Vertex Pharmaceuticals stock hits 52-week low at $377.78

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock reached a 52-week low, closing at $377.78. The biotech giant, with a market capitalization of $97.2 billion, has maintained relatively low price volatility despite recent market turbulence, according to InvestingPro data. This milestone reflects a challenging period for the biotechnology company, though its revenue grew by 10.5% over the past year. Despite the current price weakness, management has been actively buying back shares, and the company maintains strong financial health with a current ratio of 2.52. InvestingPro analysis suggests the stock may be undervalued at current levels. Vertex Pharmaceuticals, known for its focus on developing therapies for serious diseases, faces the task of reassuring investors and stabilizing its stock performance in the coming months. For deeper insights into VRTX’s valuation and growth prospects, investors can access 12 additional exclusive ProTips and comprehensive analysis through InvestingPro’s detailed research report.

In other recent news, Vertex Pharmaceuticals reported second-quarter 2025 revenue of $2.96 billion, surpassing both Truist Securities’ estimate of $2.93 billion and the consensus estimate of $2.91 billion. Despite this positive financial performance, the company faced multiple setbacks in its pain medication pipeline. Vertex’s next-generation NaV1.8 inhibitor did not achieve statistical significance on its primary endpoint, prompting H.C. Wainwright to lower its price target to $478 while maintaining a Buy rating. Similarly, Stifel reduced its price target to $455, citing challenges in the company’s pain program and a decision not to pursue a broad label for painful neuropathic pain in upcoming trials.

Bernstein SocGen adjusted its price target for Vertex to $471, maintaining a Market Perform rating, despite recent setbacks in the pain pipeline. Truist Securities also lowered its price target to $490, keeping a Buy rating, due to concerns about the company’s dependence on its cystic fibrosis treatments. BMO Capital followed suit, reducing its price target to $530 and maintaining an Outperform rating, after a Phase 2 trial failure and difficulties in obtaining FDA approval for broad labeling. These developments highlight the challenges Vertex faces in its pain treatment initiatives, as reflected in the varied analyst responses.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.